Outcome measures in rheumatologic clinical trials and systemic sclerosis

被引:24
作者
Furst, D. E. [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
Scleroderma; Outcome measures in rheumatologic clinical trials; Lung; Combined indices;
D O I
10.1093/rheumatology/ken269
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OMERACT (Outcome Measures in Rheumatologic Clinical Trials) is a loose organization of rheumatologists, epidemiologists and statisticians whose aim is to improve measurements in the rheumatic diseases. In this context, some SSc measures of response have been found to be valid: the modified Rodnan skin score, the Raynauds condition score, the forced vital capacity as part of pulmonary function tests, right heart catheterization haemodynamics, serum creatinine, blood pressure and complete blood counts in scleroderma renal crisis and serum creatine phosphokinase as a measure of muscle disease in SSc. Other measures are being tested and have nearly been validated, including the gastrointestinal questionnaire in SSc. Finally, some measures have been found wanting or are not fully testedin this case for pulmonary arterial hypertension, where effort is presently being focused. These include the echocardiogram, high-resolution CT scan of the lungs, pulmonary function tests, 6-min walking test and MRI.
引用
收藏
页码:V29 / V30
页数:2
相关论文
共 18 条
  • [1] Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease
    Arcasoy, SM
    Christie, JD
    Ferrari, VA
    Sutton, MS
    Zisman, DA
    Blumenthal, NP
    Pochettino, A
    Kotloff, RM
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (05) : 735 - 740
  • [2] An overview of economic evaluations for drugs used in rheumatoid arthritis -: Focus on tumour necrosis factor-α antagonists
    Bansback, NJ
    Regier, DA
    Ara, R
    Brennan, A
    Shojania, K
    Esdaile, JM
    Anis, AH
    Marra, CA
    [J]. DRUGS, 2005, 65 (04) : 473 - 496
  • [3] Denton CP, 1997, BRIT J RHEUMATOL, V36, P239
  • [4] Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis
    Distler, O.
    Behrens, F.
    Huscher, D.
    Foeldvari, I.
    Zink, A.
    Nash, P.
    Denton, C. P.
    Humbert, M.
    Matucci-Cerinic, M.
    Seibold, J.
    Rubin, L.
    Furst, D. E.
    [J]. RHEUMATOLOGY, 2006, 45 (12) : 1455 - 1457
  • [5] Furst D, 2007, J RHEUMATOL, V34, P1194
  • [6] Measuring outcomes in PAH - The gap between the measures that are used and their validity
    Furst, Daniel E.
    [J]. AUTOIMMUNITY, PT C: THE MOSAIC OF AUTOIMMUNITY, 2007, 1107 : 410 - 416
  • [7] MEASUREMENT OF CLINICAL-CHANGE IN PROGRESSIVE SYSTEMIC-SCLEROSIS - 1-YEAR DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF N-ACETYLCYSTEINE
    FURST, DE
    CLEMENTS, PJ
    HARRIS, R
    ROSS, M
    LEVY, J
    PAULUS, HE
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1979, 38 (04) : 356 - 361
  • [8] Furst DE, 1998, J RHEUMATOL, V25, P84
  • [9] The Health Assessment Questionnaire Disability Index and Scleroderma Health Assessment Questionnaire in Scleroderma Trials: An evaluation of their measurement properties
    Johnson, SR
    Hawker, GA
    Davis, AM
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (02): : 256 - 262
  • [10] Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study
    Khanna, D.
    Furst, D. E.
    Hays, R. D.
    Park, G. S.
    Wong, W. K.
    Seibold, J. R.
    Mayes, M. D.
    White, B.
    Wigley, F. F.
    Weisman, M.
    Barr, W.
    Moreland, L.
    Medsger, T. A., Jr.
    Steen, V. D.
    Martin, R. W.
    Collier, D.
    Weinstein, A.
    Lally, E. V.
    Varga, J.
    Weiner, S. R.
    Andrews, B.
    Abeles, M.
    Clements, P. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (10) : 1325 - 1329